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Abstract
Chronic obstructive pulmonary disease (COPD) is an inflammatory disease characterized by the progressive
deterioration of pulmonary function and increasing airway obstruction, with high morality all over the world. The
advent of high-throughput omics techniques provided an opportunity to gain insights into disease pathogenesis
and process which contribute to the heterogeneity, and find target-specific and disease-specific therapies. As an
interdispline, bioinformatics supplied vital information on integrative understanding of COPD. This review focused
on application of bioinformatics in COPD study, including biomarkers searching and systems biology. We also
presented the requirements and challenges in implementing bioinformatics to COPD research and interpreted
these results as clinical physicians.
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Introduction
Chronic obstructive pulmonary disease (COPD) is an
inflammatory disease characterized by the progressive
deterioration of pulmonary function and increasing air-
way obstruction [1,2]. It can be caused by inflammatory
responses triggered by noxious particles or gas, most
commonly from tobacco smoking and is accompanied
by chronic bronchitis and emphysema [3,4]. Some
patients go on to require long-term oxygen therapy or
even lung transplantation [3]. COPD was ranked as
fourth leading cause of death worldwide and is esti-
mated to become the top third cause of mortality by
2020 [5]. According to the data in China, COPD ranks
as the fourth leading cause of death in urban areas and
third in rural areas[6]. The high mortality and morbidity
with COPD, and its chronic progressive nature, have
promoted the need to investigate the underlying
mechanisms and identify biomarkers for diagnosis, prog-
nosis and drug target.
The understanding of COPD increased by advanced
molecular biology approaches, genetically modified ani-
mals, virally administered genes, and high-throughput
transcriptional profiling approaches. High-throughput
methodologies, such as genomics and proteomics, are
commonly used. The variety of data from biology,
mainly in the form of DNA, RNA and protein sequences
is putting heavy demand in computer sciences and com-
putational biology. Bioinformatics, including many sub-
disciplines, such as genomics, proteomics and system
biology, is an integration of mathematical, statistical,
and computational methods to analyze biological, bio-
chemical, and biophysical data. Compared to wet-lab
method, bioinformatics focused on data mining via com-
putational means. Sophisticated bioinformatics techni-
ques are developed to analyze the vast amount of data
generated from genomics and proteomics studies, such
as gene and protein function, interactions and metabolic
and regulatory pathways. However, there is still a great
challenge to combine the computer figures with clinical
data for both bench-scientists and bedside-physicians.
In COPD studies, there are usually three ways to ana-
lyze ‘omics’ data: 1) search correlation between single
gene or protein and some clinical features in order to
find diagnostic or prognostic biomarkers; 2) integrate
clinical and wet-lab information, or omics data from dif-
ferent levels for database establishment and computa-
tional models. In this current review, we discussed
application of bioinformatics in COPD study. We also
presented the requirements and challenges in imple-
menting bioinformatics to COPD research, and gave
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clinical physicians.
Application of bioinformatics in biomarker
searching
The diagnosis of COPD is based on the presence of
typical symptoms of cough and shortness of breath,
together with the presence of risk factors, and is con-
firmed by spirometry. Therefore, searching for better
biomarkers with high specificity and sensitivity indicat-
ing the staging and severity of COPD remain as major
concerns for clinical physicians. The main value of bio-
markers in COPD would be in early diagnosis and to
provide the early proof of drug efficacy during the treat-
ment [7]. As a biomarker for COPD, it is expected to be
detected in human lung fluids or tissues, sensitive to the
progress of COPD, disease-specific to COPD and asso-
ciated with the status of patients [8]. In these researches,
selected genes or proteins usually combined with several
clinical features, such as disease susceptibility, lung
function, via statistical methods, i.e. logistic regression.
Genomics
It is believed that many genetic factors increase a per-
son’s risk of developing COPD[9]. The high mortality
and morbidity associated with COPD, and its chronic
and progressive nature, has prompted the use of mole-
cular genetic studies in an attempt to identify suscept-
ibility factors for the disease. The advent of high-
throughput methodologies to study genetic background
variability, epigenetic regulation allowed us to explain
the individual variability in the susceptibility of human
diseases.
Single nucleotide polymorphism (SNP) was a common
method in COPD study. These analyses usually study a
group of candidate genes, and then perform statistical
test in different populations. The gene-related suscept-
ibility can be approached by testing or unbiased study
designs [10]. By SNP microarray, many genetic factors
were found to be related with the individual risk of
developing COPD [9]. Apart from recognized deficiency
of alpha1antitrypsin [9], genomics in COPD found that
other gene alleles, such as IREB2[11], CYP2E1 and
NAT2[12], CYP1A1, CYP1A2 and CYBA[13], TNF-a
[14] were associated with COPD susceptibility. PIM3
allele of the alpha1antitrypsin gene had an association
with the pathogenesis of COPD in the Indian population
[15]. The polymorphisms in SP-A1 and SP-A2[16],
COX2 and p53 risk-alleles [17]might be genetic factors
contributing to the susceptibility to COPD. On the
other hand, COPD could influence single gene expres-
sion as well, such as cathepsin inhibitory cystatin A[18].
COPD is featured by decline in lung function in dis-
ease progression. Therefore, except susceptibility, other
case-control genomics studies focused on the association
of several gene alleles with lung function. 105V/114V
alleles of GSTP1 and 113H/139H alleles of mEPHX and
the combination of genotypes with same alleles were
associated with imbalanced oxidative stress and lung
function in patients [19]. Polymorphisms in ADAM33
were associated with COPD and lung function decline
in long-term smokers [20] and general population [21].
The variants and their combinations of eNOS -786C,
-922G, and 4A alleles in endothelial cells contribute to
disturbed pulmonary function and oxidative stress in
COPD[22].
An interleukin13 polymorphism in the promoter
region may modulate the adverse effects of cigarette
smoking on pulmonary function in long-term cigarette
smokers [23]. These genomics findings suggested that
environmental influences were important in COPD.
Genetic polymorphisms contributed to the development
of COPD, especially to the declined lung function. The
diversity in human genes could help us to understand
the susceptibility among different ethics and different
populations. The dissection of the genetic basis of com-
plex diseases and the development of highly individua-
lized therapies remain lofty but achievable goals [24].
Proteomics
Proteomics is the systematic study of the many and
diverse properties of protein profiles in a parallel man-
ner with the aim of providing detailed descriptions of
the structure, function and control of biological systems
in health and disease [25]. A major research objective is
to search for biomarkers in complex biological fluids.
The proteomic analysis highlights the avenues to inves-
tigate protein profiles of cells, biopsies and fluids,
explore protein-based mechanisms of human diseases,
define subgroups of disease, and identify novel biomar-
kers for diagnosis, therapy and prognosis of multiple
diseases and discover new targets for drug development.
In particular, the application of complementary
approaches, including gel- and liquid chromatography
mass spectrometry-based proteomic techniques on spu-
tum and/or bronchoalveolar lavage may provide a better
understanding of the proteome differentially expressed
among the courses, severities and populations of COPD
[7]. We have previously reviewed the clinical studies on
COPD proteomics, highlighted the proteomic-oriented
methods applied and evaluated the diagnostic or prog-
nostic values of potential biomarkers [8]. Those studies
mainly focused on disease classification, biomarker
detection, or identification of mechanism, while the
three components are related with each other in COPD
(Figure 1).
An important goal of proteomic studies is to under-
stand biological roles of specific proteins and develop
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proteomics studies performed in COPD patients, several
potential proteins have been regarded as biomarkers.
For example, matrix metalloproteinase (MMP)-13 and
thioredoxin-like 2 in lungs increased in patients with
COPD [27]. The serine and MMP proteinase network
was considered as an important feature in predicting
clinical worsening of airway obstruction [28]. Pulmonary
surfactant A was found to link to the pathogenesis of
COPD and could be considered as a potential COPD
biomarker [29]. Proteomic screening of sputum yields
potential biomarkers of inflammation [30]. Airway and
parenchymal phenotypes of COPD were suggested to be
associated with unique systemic serum biomarker pro-
files [31]. The utility of proteomic profiling would
improve the understanding of molecular mechanisms
involved in cigarette smoking-related COPD by identify-
ing plasma proteins that correlate with declined lung
function [32]. The concentrations of neutrophil defen-
sins 1 and 2, calgranulin A, and calgranulin B were ele-
vated in smokers with COPD when compared to
asymptomatic smokers [33]. Other candidates, like
serum amyloid A [34], plasma retinal-binding protein,
apolipoprotein E, inter-alpha-trypsininhibitor heavy
chain H4, and glutathione peroxidase[35], were also
been detected in plasma in COPD patients by proteo-
mics approaches.
Metabolomics
Metabolomics is a global way to understanding regula-
tion of metabolic pathways and metabolic networks of a
biologic system[36]. Metabolites trigonelline, hippurate
and formate in urinary were identified to be associated
with baseline lung function of COPD patients and con-
sidered to reflect lifestyle differences affecting overall
health [37]. Another way to analyze omics data is clus-
tering data to form a specific pattern for different
groups by principal component analysis (PCA). Combi-
nation of PCA and metabolomics identified the meta-
bolic fingerprint of exhaled breath condensate of COPD
patients [38].
Multiplexed ELISA
A recent advancement in ELISA is the multiplexed
ELISA which could determine multiple proteins within
as i n g l et i s s u es a m p l e .I th a sr e c e n t l yb e e ns h o w nt ob e
more sensitive than standard ELISA once optimized for
a particular cytokine [39-41] and could be a promising
diagnostic assay in lung diseases [42]. Moreover, the
measurement of multiple cytokines is required for many
diseases, particularly those like COPD that arise from a
complex process of initiation and progression of inflam-
mation network. Simultaneous detection of multiple
cytokines will undoubtedlyp r o v i d eam o r ep o w e r f u l
tool to quantifiably measure cytokines in different stages
of COPD. With help of this high-throughput measure-
ment platform, we could integrate both biologic and
clinical data to inform predictive multiscale models ran-
ging from the molecular to the organ levels, as shown in
Figure 2. For example, the integration of IL-9 pathway
and CCR3 pathway between biological function and
pathology demonstrated cell proliferation-related remo-
deling, intracellular signal-associated inflammatory
responses and over-activation of kinases-correlated
emphysema in the pathogenesis of COPD. We propose
this new way will increase our insight into disease pro-
cess and have great potential to identify new biomarkers
for disease diagnosis as well as novel therapeutic targets.
Systems biology and database establishment
The difficulties encountered whilst exploring pathogen-
esis and searching for biomarkers may be due in part to
the complex nature of COPD, which comprises a broad
spectrum of histopathological findings and respiratory
symptoms [43]. All genetic information and molecular
knowledge need to be semantically incorporated and
associated with clinical and experimental data. System
biology in COPD (as reviewed before[44]) presented a
manifold understanding of the complexity of COPD,
therefore advanced biomedical research and drug devel-
opment. This approach relies on global genome, tran-
scriptome, proteome, and metabolome data sets
Figure 1 Overview of the utility of bioinformatics in chronic
obstructive pulmonary disease. Both genomics and proteomics
provide information on candidates. By searching in various datasets
and combining with clinical profiles, ‘omis’ studies may help to
explain questions on disease classification, biomarker detection, and
identification of mechanism.
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throughput measurement platforms and integrated with
biologic and clinical data to inform predictive multidi-
mensional models ranging from the molecular to the
organ levels[45].
Comandini etc. [46] assayed a number of published
studies by creating a smoker datasets on which to per-
form data-mining analysis. They utilized Ingenuity Path-
ways Analysis, a web-based application that enables
identifying relationships, biological mechanisms, func-
tions, and pathways of relevance associated with the
molecules under study. Their findings supported the
central role of anti-oxidant genes in smoking population
and suggested Nrf2 may be a COPD risk biomarker. A
brand new knowledge base was generated from clinical
and experimental data for COPD based on BioXM soft-
ware platform [47]. This integrated database reduced
implementation time and effort for the knowledge base
compared to similar systems a n dp r o v i d e daf r e e ,c o m -
prehensive, easy to use resource for all COPD related
clinical research.
Clinical profiles could also be considered as a form of
omics data since it provided a large quantity of patients’
information in a direct conservative way. An in-silico
research applied various explorative analysis techniques
(PCA, MCA, MDS) and unsupervised clustering
methods (KHM) to study a large dataset, acquired from
415 COPD patients, to assess the presence of hidden
structures in data corresponding to the different COPD
phenotypes observed in clinical practice. This study may
be considered as a methodological example showing
possible applications of intelligent data analysis and
visual exploratory techniques to investigate clinical
aspects of chronic pathologies where a mathematical
referring model is generally missing[48].
How to understand bioinformatics as clinical
physicians
COPD has been approached by genomic and proteomic
technologies to allow us to identify patterns of gene/
protein expression that track with clinical disease or to
identify new pathways involved in disease pathogenesis.
The results from these initial studies highlight the
potential for these omics approaches to reveal novel
insights into the pathogenesis of COPD and provide
new tools to improve diagnosis, clinical classification,
course prediction, and response to therapy. Existing
knowledge such as genotype-phenotype relations or sig-
nal transduction pathways must be semantically inte-
grated and dynamically organized into structured
networks that are connected with clinical and experi-
mental data. This will require collaboration among
Figure 2 The integration of IL-9 pathway and CCR3 pathway between biological function and pathology demonstrated cell
proliferation-related remodeling, intracellular signal-associated inflammatory responses and over-activation of kinases-correlated
emphysema in the pathogenesis of COPD.
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technologies, bioinformatics, and clinical medicine for
the disease. More and more clinical physicians began to
realize the promise of these studies and the potential to
revolutionize the diagnosis and treatment of COPD,
while obstacles still existed between these laboratory
findings and their applications in clinical practice.
Omics results need to be interpreted by translational
medicine and systems biology. Since the vocabulary of
systems biology is different than that of molecular biol-
ogy or clinical research, the biggest challenge is the shift
in thinking[49].
Instead of a single-factor approach, which is highly
effective in the lab, we need to think globally as clinical
physicians. We need to shift from an approach that tries
to explain lung pathogenesis by “one molecule, one cell
type” to approach that looks at the network of interac-
tions between multiple molecules, pathways, and cells.
Given that all the samples were collected from human,
it would be of great significance to standardize patient
groups. Criteria of clinical informatics and medical
informatics, including age, gender, smoking history, sta-
ging, complications and clinical signs as well as exami-
nations, should be fully considered before and after any
o m i c si n v e s t i g a t i o n .W ea l s on e e dt op a ya t t e n t i o nt o
the relation between clinical data and laboratory find-
ings. For this to occur, a well-done history and physical
examination would be helpful to supplement these
laboratory figures by providing multiple features of
human COPD.
Although all of these exciting technological advances
that exponentially increase the levels of knowledge
about every disease and model serve as facilitators of
integration, they do not inherently provide integrative
models of disease. Therefore, we proposed that digitaliz-
ing essential clinical profiles, such as symptoms and
signs, by questionnaires and/or scores, would provide
direct vision for physicians and shrink the distance
between lab discovery and clinical condition. The com-
bination of epidemiologists, clinicians, geneticists and
specialists in bioinformatics, in addition to specialists in
disciplines less familiar to epidemiologists, is critical to
be prepared for new phenotypic characterizations based
on transcriptome and proteome [50]. Even though we
have spotted considerable advancement in bioinfor-
matics, it still calls for more collaboration to fulfill its
potential (Figure 3). Interdisciplinary teams should allow
us to access omics datasets integratively and generate a
global model of COPD. It is important to have a special
attention from proteomic scientists to explore the com-
bination between advanced proteomic biotechnology,
clinical proteomics, tissue imaging and profiling, and
organ dysfunction score systems, to improve the clinical
outcomes of these patients [51]. There is still a great
need to explore the COPD-specific and/or related tran-
scriptional factors and regulation networks generated
from omics and bioinformatics like in other diseases
[41].
Conclusions
The use of high-throughput techniques for gene and
protein expression profiling and of computerized data-
bases has become a mainstay of biomedical research.
There is a need to perform omics studies on patients
with COPD, describing the association with the disease
in terms of specificity, severity, progress and prognosis
and monitoring the efficacy of therapies. These omics
analysis highlight the ways to investigate protein profiles
of cells, biopsies and fluids, explore protein-based
mechanisms of human diseases, identify novel biomar-
kers for diagnosis, therapy and prognosis of multiple
diseases and discover new targets for drug development,
as shown in Figure 3. Although the number of clinical
studies on COPD is limited, they still serve as the out-
standing initiation for proteomic research in such a
complex disease. The analysis of protein profiles that
are up- or down-regulated, modified, secreted in the air-
ways during the disease may yield vital evidences to
understand the pathogenesis and discover new therapeu-
tic targets for the disease (Figure 4) [52]. With many
guidelines now in place and model studies on which to
design future experiments, there is reason to be optimis-
tic that candidate protein biomarkers will be discovered
using proteomics and translated into clinical assays[53].
With better study design standardization and the imple-
mentation of novel technologies to reach the optimal
research standard, there is enough reason be optimistic
Figure 3 Bioinformatics begin to take part in COPD
investigation. The collaboration of epidemiologists, clinicians,
geneticists and specialists in bioinformatics, in addition to specialists
in disciplines less familiar to epidemiologists, is critical for further
study. More co-operations are still needed.
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cations [54]. Clinical bioinformatics on COPD could be
achieved from the combination of clinical informatics,
medical informatics, bioinformatics and informatics by
collaborations among clinicians, bioinformaticians, com-
puter scientists, biologists, and mathematicians.
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100057_at Cluster Incl AI838320:UI-M-AO0-aby-f-05-0-UI.s1 Mus musculus cDNA, 3  end /clone=UI-M-AO0-aby-f-05-0-UI /clone_end=3  /gb=AI838320 /gi=5472533 /ug=Mm.4467 /len=529
100059_at cytochrome b-245, alpha polypeptide
100069_at cytochrome P450, 2f2
100311_f_at eosinophil-associated ribonuclease 1
100331_g_at thioredoxin peroxidase, pseudogene 1
100380_at H3 histone, family 3A
100397_at TYRO protein tyrosine kinase binding protein
100569_at annexin A2
100583_at Cluster Incl J00475:Mouse germline IgH chain gene, DJC region- segment D-FL16.1 /cds=(0,1033) /gb=J00475 /gi=194417 /ug=Mm.6160 /len=1034
100597_at glycogenin 1
100711_at ribosomal protein L10A
100944_at Cluster Incl AA958903:ua19f08.r1 Mus musculus cDNA, 5  end /clone=IMAGE-1347207 /clone_end=5  /gb=AA958903 /gi=3125133 /ug=Mm.6381 /len=384
100946_at neuraminidase 1
101019_at cathepsin C
101045_at hydroxyacyl-Coenzyme A dehydrogenase, type II
101048_at protein tyrosine phosphatase, receptor type, C
101137_at ribosomal protein S3
101212_at ribosomal protein S7
101482_at protein phosphatase 1, catalytic subunit, gamma isoform
101656_f_at Cluster Incl U60442:Mus musculus Ig kappa light chain mRNA, partial cds /cds=(0,363) /gb=U60442 /gi=1421746 /ug=Mm.30406 /len=391
101753_s_at P lysozyme structural
101781_f_at Cluster Incl V00754:Mouse gene coding for embryonic H3 histone /cds=(0,407) /gb=V00754 /gi=51297 /ug=Mm.57118 /len=408
101876_s_at histocompatibility 2, T region locus 10
101881_g_at procollagen, type XVIII, alpha 1
101908_s_at CEA-related cell adhesion molecule 2
101955_at heat shock 70kD protein 5 (glucose-regulated protein, 78kD)
101973_at Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2
102029_at interleukin 16
102104_f_at Cluster Incl AI504305:vl04g11.x1 Mus musculus cDNA, 3  end /clone=IMAGE-963236 /clone_end=3  /gb=AI504305 /gi=4402156 /ug=Mm.42485 /len=580
102156_f_at Cluster Incl M80423:Mus castaneus IgK chain gene, C-region, 3  end /cds=(0,322) /gb=M80423 /gi=196865 /ug=Mm.46804 /len=323
102196_at Cluster Incl U37413:Guanine nucleotide binding protein, alpha 11 /cds=(57,1136) /gb=U37413 /gi=1051237 /ug=Mm.989 /len=1342
102207_at delta-like homolog (Drosophila)
102208_at sialyltransferase 10 (alpha-2,3-sialyltransferase VI)
102217_at G protein-coupled receptor kinase 5
102372_at Cluster Incl M90766:Mouse Ig active joining chain (J chain) mRNA of the b allele, complete cds /cds=(21,500) /gb=M90766 /gi=194473 /ug=Mm.1192 /len=501
102585_f_at Cluster Incl AB017349:Mus musculus mRNA for immunoglobulin light chain V region, partial cds /cds=(0,353) /gb=AB017349 /gi=4519566 /ug=Mm.57251 /len=360
102641_at SFFV proviral integration 1
102767_at EST AA536815
102806_g_at CEA-related cell adhesion molecule 1
102906_at T-cell specific GTPase
102920_at Cluster Incl AW215585:up06c04.x1 Mus musculus cDNA, 3  end /clone=IMAGE-2651238 /clone_end=3  /gb=AW215585 /gi=6526261 /ug=Mm.1622 /len=329
102995_s_at granzyme A
103035_at ATP-binding cassette, sub-family B (MDR/TAP), member 2
103089_at CD48 antigen
103200_at Cluster Incl AA711773:vu58g05.r1 Mus musculus cDNA, 5  end /clone=IMAGE-1195640 /clone_end=5  /gb=AA711773 /gi=2721691 /ug=Mm.1902 /len=473
103240_f_at eosinophil-associated ribonuclease 3
103448_at S100 calcium binding protein A8 (calgranulin A)
103462_at Cluster Incl AW122239:UI-M-BH2.2-aov-f-02-0-UI.s1 Mus musculus cDNA, 3  end /clone=UI-M-BH2.2-aov-f-02-0-UI /clone_end=3  /gb=AW122239 /gi=6097702 /ug=Mm.2173 /len=549
103560_at Cluster Incl AW124401:UI-M-BH2.1-ape-d-04-0-UI.s1 Mus musculus cDNA, 3  end /clone=UI-M-BH2.1-ape-d-04-0-UI /clone_end=3  /gb=AW124401 /gi=6099931 /ug=Mm.19119 /len=217
103887_at S100 calcium-binding protein A9 (calgranulin B)
104014_at hemochromatosis
104071_at Cluster Incl AI852433:UI-M-BH0-ajo-g-04-0-UI.s1 Mus musculus cDNA, 3  end /clone=UI-M-BH0-ajo-g-04-0-UI /clone_end=3  /gb=AI852433 /gi=5496304 /ug=Mm.21639 /len=544
104093_at lymphocyte specific 1
104173_at Cluster Incl AA797989:ub60d04.r1 Mus musculus cDNA, 5  end /clone=IMAGE-1382119 /clone_end=5  /gb=AA797989 /gi=2860944 /ug=Mm.27253 /len=413
104267_at Cluster Incl AI844736:UI-M-AL1-ahq-c-10-0-UI.s1 Mus musculus cDNA, 3  end /clone=UI-M-AL1-ahq-c-10-0-UI /clone_end=3  /gb=AI844736 /gi=5488642 /ug=Mm.28535 /len=406
104298_at Cluster Incl AI842544:UI-M-AQ1-aea-e-05-0-UI.s1 Mus musculus cDNA, 3  end /clone=UI-M-AQ1-aea-e-05-0-UI /clone_end=3  /gb=AI842544 /gi=5476757 /ug=Mm.22337 /len=457
104415_at EST AI461938
104606_at CD52 antigen
104735_at Cluster Incl AI842065:UI-M-AN1-afg-a-10-0-UI.s1 Mus musculus cDNA, 3  end /clone=UI-M-AN1-afg-a-10-0-UI /clone_end=3  /gb=AI842065 /gi=5476278 /ug=Mm.24647 /len=444
160108_at p8 protein
160117_at Cluster Incl AI850638:UI-M-BG1-aik-e-06-0-UI.s1 Mus musculus cDNA, 3  end /clone=UI-M-BG1-aik-e-06-0-UI /clone_end=3  /gb=AI850638 /gi=5494544 /ug=Mm.19258 /len=381 /NOTE=rep
160156_at Cluster Incl AA981015:vx55c11.r1 Mus musculus cDNA, 5  end /clone=IMAGE-1279124 /clone_end=5  /gb=AA981015 /gi=3159551 /ug=Mm.22383 /len=343 /NOTE=replacement for probe 
160386_at Cluster Incl AI835981:UI-M-AQ0-aah-d-09-0-UI.s2 Mus musculus cDNA, 3  end /clone=UI-M-AQ0-aah-d-09-0-UI /clone_end=3  /gb=AI835981 /gi=5470234 /ug=Mm.30099 /len=318 /NOTE=r
160388_at Cluster Incl AI848668:UI-M-AH1-agv-a-10-0-UI.s1 Mus musculus cDNA, 3  end /clone=UI-M-AH1-agv-a-10-0-UI /clone_end=3  /gb=AI848668 /gi=5492539 /ug=Mm.30119 /len=421 /NOTE=re
160402_at ribosomal protein L13
160493_at Cd63 antigen
160495_at aryl-hydrocarbon receptor
160502_at cellular repressor of E1A-stimulated genes
Statistical analysis
Criteria for genes 
Differentially 
expressed
Targets
Pathophysiologies
Hierarchical Clustering
Real Time Quantitative PCR:
Assess Gene Expression
Figure 4 Clinical bioinformatics can be generated from the analysis of COPD-specific pathological alterations. Patients with COPD can
be selected by clinical informatics and criteria and the specific area is selected by micro-dissection. The tissue can be used for genomic (or
proteomic) analysis and identified biomarkers are validated for the understanding of the pathogenesis.
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